Stocks · News reference
UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 11:02 AM
- Checked
- Aug 20, 2026, 11:25 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — UroGen Pharma Ltd. (URGN)
Filed: 2026-08-20 AccNo: 0001437749-26-028590 Size: 151 KB Item 8.01: Other Events
Read original at edgarUroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application
Read original at benzinga